RestorGenex Corporation. is a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health. The Company’s proposed product portfolio includes a cosmeceutical product line. The Company is engaged in product development for both the cosmeceutical market, as well as the prescription dermatology market. The Company’s HYG-102, a soft estrogen, for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen, for the treatment of androgen excess, e.g. acne, male-pattern baldness; P529, for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease and the bullous blistering diseases; HYG-102, is for vulvar and vaginal atrophy (VVA); HYG-102 and HYG-440 target hormonal aging in women which radically affects the mucous membranes.